<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">sibmed</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский научный медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Сибирский научный медицинский журнал</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2410-2512</issn><issn pub-type="epub">2410-2520</issn><publisher><publisher-name>ИЦиГ СО РАН</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15372/SSMJ20180609</article-id><article-id custom-type="elpub" pub-id-type="custom">sibmed-84</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>ПАТОМОРФОЛОГИЧЕСКИЙ АНАЛИЗ ТРЕПАНОБИОПТАТОВ ПРИ ХРОНИЧЕСКОМ МИЕЛОЛЕЙКОЗЕ И ХРОНИЧЕСКОМ ЛИМФОЛЕЙКОЗЕ: ОЦЕНКА ПРОГНОСТИЧЕСКОЙ ЗНАЧИМОСТИ МИЕЛОФИБРОЗА ПРИ СОПОСТАВЛЕНИИ С КЛИНИЧЕСКИМИ ДАННЫМИ</article-title><trans-title-group xml:lang="en"><trans-title>PATHOMORPHOLOGICAL ANALYSIS OF TREPANOBIOPTATES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOCYTIC LEUKEMIA: ASSESSMENT OF THE PROGNOSTIC VALUE OF MYELOFIBROSIS WHEN COMPARED WITH CLINICAL DATA</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Долгих</surname><given-names>Т. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Dolgikh</surname><given-names>T. Y.</given-names></name></name-alternatives><email xlink:type="simple">pathol@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Виноградова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vinogradova</surname><given-names>E. V.</given-names></name></name-alternatives><email xlink:type="simple">pathol@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Капустина</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kapustina</surname><given-names>V. I.</given-names></name></name-alternatives><email xlink:type="simple">pathol@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сенчукова</surname><given-names>С. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Senchukova</surname><given-names>S. R.</given-names></name></name-alternatives><email xlink:type="simple">pathol@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Институт молекулярной патологии и патоморфологии ФИЦ фундаментальной и трансляционной медицины<country>Россия</country></aff><aff xml:lang="en">Institute of Molecular Pathology and Pathomorphology, Federal Research Center for Fundamental and Translational Medicine<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>20</day><month>02</month><year>2019</year></pub-date><volume>38</volume><issue>6</issue><fpage>57</fpage><lpage>63</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Долгих Т.Ю., Виноградова Е.В., Капустина В.И., Сенчукова С.Р., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Долгих Т.Ю., Виноградова Е.В., Капустина В.И., Сенчукова С.Р.</copyright-holder><copyright-holder xml:lang="en">Dolgikh T.Y., Vinogradova E.V., Kapustina V.I., Senchukova S.R.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://sibmed.elpub.ru/jour/article/view/84">https://sibmed.elpub.ru/jour/article/view/84</self-uri><abstract><p>Цель исследования - изучить взаимосвязь качественных и количественных характеристик миелофиброза и клинических проявлений хронического миелолейкоза и хронического лимфолейкоза. Материал и методы. Проведено комплексное патоморфологическое исследование трепанобиоптатов подвздошной кости и комплексное клинико-лабораторное и инструментальное обследование 154 больных хроническим миелолейкозом и хроническим лимфолейкозом. Результаты. У пациентов в хронической фазе хронического миелолейкоза в дебюте заболевания и при потере ответа на химиотерапию наибольшая площадь селезенки выявлена при выраженном миелофиброзе, наименьшая - при его отсутствии. У пациентов в дебюте или рецидиве хронического лимфолейкоза спленомегалия, гепатомегалия и генерализованная лимфаденопатия наиболее часто встречаются у пациентов с миелофиброзом по сравнению с пациентами без миелофиброза. Выраженный миелофиброз во всех случаях был ассоциирован с гепатоспленомегалией. При сопоставлении морфометрических и клинических данных установлено, что в хронической фазе хронического миелолейкоза в дебюте заболевания относительная площадь очагов начального миелофиброза более 60 %, относительная площадь очагов выраженного миелофиброза более 40 % и гранулоцитарно-мегакариоцитарный подтип опухолевого поражения костного мозга ассоциированы с развитием рецидива или прогрессии после 1-й или 2-й линии химиотерапии. В дебюте хронического лимфолейкоза относительная площадь очагов начального миелофиброза более 20 %, относительная площадь очагов выраженного миелофиброза более 11 % и диффузный тип опухолевого поражения костного мозга ассоциированы с развитием рецидива или прогрессии после 1-й или 2-й линии химиотерапии.</p></abstract><trans-abstract xml:lang="en"><p>The aim of the study was to study the relationship between the qualitative and quantitative characteristics of myelofibrosis and the clinical manifestations of chronic myeloid leukemia and chronic lymphocytic leukemia. Material and methods. A complex pathomorphological study of ilium bone trepanobioptates and a complex clinical-laboratory and instrumental examination of 154 patients with chronic myeloid leukemia and chronic lymphocytic leukemia were performed. Results. In patients in the chronic phase of chronic myeloid leukemia in the onset of the disease and with a loss of response to chemotherapy, the largest area of the spleen was detected with pronounced myelofibrosis, the smallest - in the absence of myelofibrosis. In patients in the onset or relapse of chronic lymphocytic leukemia, splenomegaly, hepatomegaly and generalized lymphadenopathy are most common in patients with myelofibrosis compared to patients without myelofibrosis. The expressed myelofibrosis in all cases was associated with hepatosplenomegaly. Comparing the morphometric and clinical data, it is established that in the chronic phase of chronic myeloid leukemia in the onset of the disease, the relative area of foci of initial myelofibrosis more than 60 %, the relative area of foci of pronounced myelofibrosis more than 40 %, and the granulocyte-megakaryocytic subtype of bone marrow tumor are associated with the development of relapse or progression of disease after 1st or 2nd line of chemotherapy. In the onset of chronic lymphocytic leukemia, the relative area of foci of initial myelofibrosis more than 20 %, the relative area of foci of pronounced myelofibrosis more than 11 %, and the diffuse type of bone marrow tumor lesion are associated with the development of relapse or progression of disease after 1st or 2nd line of chemotherapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хронический миелолейкоз</kwd><kwd>хронический лимфолейкоз</kwd><kwd>миелофиброз</kwd><kwd>клиническая и прогностическая значимость</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic myeloid leukemia</kwd><kwd>chronic lymphocytic leukemia</kwd><kwd>myelofibrosis</kwd><kwd>clinical and prognostic value</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Домникова Н.П., Долгих Т.Ю. Распространенность миелофиброза при хроническом миелолейкозе, множественной миеломе и хроническом лимфолейкозе в различные фазы заболеваний // Сиб. науч. мед. журн. 2016. (5). 53-57.</mixed-citation><mixed-citation xml:lang="en">Домникова Н.П., Долгих Т.Ю. Распространенность миелофиброза при хроническом миелолейкозе, множественной миеломе и хроническом лимфолейкозе в различные фазы заболеваний // Сиб. науч. мед. журн. 2016. (5). 53-57.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Программное лечение заболеваний системы крови: Сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови / ред. В.Г. Савченко. М.: Практика, 2012. 1056 с.</mixed-citation><mixed-citation xml:lang="en">Программное лечение заболеваний системы крови: Сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови / ред. В.Г. Савченко. М.: Практика, 2012. 1056 с.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ругаль В.И., Бессмельцев С.С., Семенова Н.Ю. Особенности нишеобразующих структур и стромы костного мозга больных хроническим лимфоцитарным лейкозом // Medline.Ru. 2013. 14. (2). 347-361.</mixed-citation><mixed-citation xml:lang="en">Ругаль В.И., Бессмельцев С.С., Семенова Н.Ю. Особенности нишеобразующих структур и стромы костного мозга больных хроническим лимфоцитарным лейкозом // Medline.Ru. 2013. 14. (2). 347-361.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tchernia G., Jacquillat C., Boivin P., Lesty C., Duault M.T., Monconduit M., Belabbes S., Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. 1981. 48. (1). 198-206.</mixed-citation><mixed-citation xml:lang="en">Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tchernia G., Jacquillat C., Boivin P., Lesty C., Duault M.T., Monconduit M., Belabbes S., Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. 1981. 48. (1). 198-206.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Buesche G., Georgii A., Duensing A., Schmeil А., Schlue J., Kreipe H. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia // Hum. Pathol. 2003. 34. (4). 391-401.</mixed-citation><mixed-citation xml:lang="en">Buesche G., Georgii A., Duensing A., Schmeil А., Schlue J., Kreipe H. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia // Hum. Pathol. 2003. 34. (4). 391-401.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Buesche G., Hehlmann R., Hecker H., Heimpel H., Heinze B., Schmeil A., Pfirrmann M., Gomez G., Tobler A., Herrmann H., Kappler M., Hasford J., Buhr T., Kreipe H.H., Georgii A. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial // Leukemia. 2003. 17. 2444-2453.</mixed-citation><mixed-citation xml:lang="en">Buesche G., Hehlmann R., Hecker H., Heimpel H., Heinze B., Schmeil A., Pfirrmann M., Gomez G., Tobler A., Herrmann H., Kappler M., Hasford J., Buhr T., Kreipe H.H., Georgii A. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial // Leukemia. 2003. 17. 2444-2453.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Burkhardt R., Bartl R., Jager K., Frisch B., Kettner G, Mahl G., Sund M. Working classification of chronic myeloproliferative disorders based on histological, haematological and clinical findings // J. Clin. Pathol. 1986. 39. 237-252.</mixed-citation><mixed-citation xml:lang="en">Burkhardt R., Bartl R., Jager K., Frisch B., Kettner G, Mahl G., Sund M. Working classification of chronic myeloproliferative disorders based on histological, haematological and clinical findings // J. Clin. Pathol. 1986. 39. 237-252.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Clough V., Geary G.C., Hashmi K. Myelofibrosis in chronic granulocytic leukemia // Br. J. Haematol. 1979. 42. 515-526.</mixed-citation><mixed-citation xml:lang="en">Clough V., Geary G.C., Hashmi K. Myelofibrosis in chronic granulocytic leukemia // Br. J. Haematol. 1979. 42. 515-526.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M.F., Lawler J., Hynes R.O., Boivin J.P., Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo // Cell. 1998. 93. 1159.</mixed-citation><mixed-citation xml:lang="en">Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M.F., Lawler J., Hynes R.O., Boivin J.P., Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo // Cell. 1998. 93. 1159.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Döhner H., Hillmen P., Keating M.J., Montserrat E., Rai K.R., Kipps T.J. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines // Blood. 2008. 111. (12). 5446-5456.</mixed-citation><mixed-citation xml:lang="en">Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Döhner H., Hillmen P., Keating M.J., Montserrat E., Rai K.R., Kipps T.J. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines // Blood. 2008. 111. (12). 5446-5456.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kantarjian H.M., Bueso-Ramos C.E., Talpaz M., O’Brien S., Giles F., Faderl S., Wierda W., Beth Rios M., Shan J., Cortes J. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy // Cancer. 2005. 104. (4). 777-780.</mixed-citation><mixed-citation xml:lang="en">Kantarjian H.M., Bueso-Ramos C.E., Talpaz M., O’Brien S., Giles F., Faderl S., Wierda W., Beth Rios M., Shan J., Cortes J. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy // Cancer. 2005. 104. (4). 777-780.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kimura A., Hyodo H., Nakata Y., Kuramoto A. Chronic lymphocytic leukemia associated with bone marrow fibrosis: Possible role of interleukin 1α in the pathogenesis // Am. J. Hematol. 1993. 43. 47-50.</mixed-citation><mixed-citation xml:lang="en">Kimura A., Hyodo H., Nakata Y., Kuramoto A. Chronic lymphocytic leukemia associated with bone marrow fibrosis: Possible role of interleukin 1α in the pathogenesis // Am. J. Hematol. 1993. 43. 47-50.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lazzarino M., Morra E., Castello A., Inverardi D., Coci A., Pagnucco G., Magrini U., Zei G., Bernasconi C. Myelofibrosis in chronic granulocytic leukemia: clinicopathological correlation and prognostic significance // Br. J. Haematol. 1986. 64. 227-240.</mixed-citation><mixed-citation xml:lang="en">Lazzarino M., Morra E., Castello A., Inverardi D., Coci A., Pagnucco G., Magrini U., Zei G., Bernasconi C. Myelofibrosis in chronic granulocytic leukemia: clinicopathological correlation and prognostic significance // Br. J. Haematol. 1986. 64. 227-240.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rankin E.B., Narla A., Park J.K., Lin S., Sakamoto K.M. Biology of the bone marrow microenvironment and myelodysplastic syndromes // Mol. Genet. Metab. 2015. Vol. 116 (1-2). P. 24-28.</mixed-citation><mixed-citation xml:lang="en">Rankin E.B., Narla A., Park J.K., Lin S., Sakamoto K.M. Biology of the bone marrow microenvironment and myelodysplastic syndromes // Mol. Genet. Metab. 2015. Vol. 116 (1-2). P. 24-28.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tadmor T., Shvidel L., Aviv A., Ruchlemer R., Bairey O., Yuklea M., Herishanu Ya., Braester A., Levene N., Vernea F., Ben-Ezra J., Bejar J., Polliack A. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications // Cancer. 2013. 119. (10). 1853-1859.</mixed-citation><mixed-citation xml:lang="en">Tadmor T., Shvidel L., Aviv A., Ruchlemer R., Bairey O., Yuklea M., Herishanu Ya., Braester A., Levene N., Vernea F., Ben-Ezra J., Bejar J., Polliack A. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications // Cancer. 2013. 119. (10). 1853-1859.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Thiele J., Kvasnicka H.M. Myelofibrosis - What′s in a Name? // Pathobiology. 2007. 74. (2). 89-96.</mixed-citation><mixed-citation xml:lang="en">Thiele J., Kvasnicka H.M. Myelofibrosis - What′s in a Name? // Pathobiology. 2007. 74. (2). 89-96.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity // Haematologica. 2005. 90. 1128-1132.</mixed-citation><mixed-citation xml:lang="en">Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity // Haematologica. 2005. 90. 1128-1132.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Thiele J., Kvasnicka H.M., Titius B.R., Parpert U., Nebel R., Zankovich R., Dienemann D., Stein H., Diehl V., Fischer R. Histological features of prognostic significance in CML: An immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow // Ann. Hematol. 1993. 66. 291-302.</mixed-citation><mixed-citation xml:lang="en">Thiele J., Kvasnicka H.M., Titius B.R., Parpert U., Nebel R., Zankovich R., Dienemann D., Stein H., Diehl V., Fischer R. Histological features of prognostic significance in CML: An immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow // Ann. Hematol. 1993. 66. 291-302.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Weistner A., Rosenwald A., Barry T.S. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile // Blood. 2003. 101. 4944-4951.</mixed-citation><mixed-citation xml:lang="en">Weistner A., Rosenwald A., Barry T.S. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile // Blood. 2003. 101. 4944-4951.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
